|
Volumn 50, Issue 2, 2002, Pages 253-258
|
Cost effectiveness of combination therapy for hepatitis C: A decision analytic model
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA INTERFERON;
RIBAVIRIN;
AGE;
ANALYTIC METHOD;
ARTICLE;
COMBINATION CHEMOTHERAPY;
COST EFFECTIVENESS ANALYSIS;
DECISION MAKING;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG COST;
FEMALE;
GENOTYPE;
HEPATITIS C;
HUMAN;
MALE;
MONOTHERAPY;
PRIORITY JOURNAL;
QUALITY OF LIFE;
UNITED KINGDOM;
ADULT;
AGED;
ANTIVIRAL AGENTS;
COHORT STUDIES;
COST-BENEFIT ANALYSIS;
DECISION SUPPORT TECHNIQUES;
DRUG COMBINATIONS;
FEMALE;
HEALTH RESOURCES;
HEALTH STATUS;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON-ALPHA;
LIVER TRANSPLANTATION;
MALE;
MARKOV CHAINS;
MIDDLE AGED;
QUALITY-ADJUSTED LIFE YEARS;
RIBAVIRIN;
SENSITIVITY AND SPECIFICITY;
|
EID: 0036153381
PISSN: 00175749
EISSN: None
Source Type: Journal
DOI: 10.1136/gut.50.2.253 Document Type: Article |
Times cited : (58)
|
References (37)
|